- Enable Medicine is at the forefront of using
generative AI models to search vast cellular atlases of disease
to discover new therapeutic insights
- Partnership will greatly boost the two companies' drug
discovery and development capabilities
- It comes after their first collaboration that led to
Ennovate Pharma SAS, working on highly promising targets in
autoimmune and inflammatory diseases
PALO ALTO, Calif. and
MENLO PARK, Calif.,
Dec. 12,
2024 /PRNewswire/ -- General Inception, a global
biotech company igniter, and Enable Medicine, a leader in AI-led
data analysis for biological research and drug discovery, today
announce an equity and strategic partnership which will amplify
their joint drug discovery capabilities. As part of this
partnership, General Inception is acquiring Enable for an
undisclosed amount.
The strategic partnership will give General Inception greater
access to Enable Medicine's biological data platform, benefiting
life science and biopharmaceutical researchers, while Enable
Medicine will benefit from General Inception's drug development
expertise and biotech ecosystem.
Power of generative biological search
Enable Medicine harnesses the revolutionary capabilities of AI
to guide novel insights into biology and medicine. The platform
unlocks the power of generative biological search, which uses
cutting-edge AI models to search maps of disease for novel drug
targets and indications. The approach prioritizes indexing high
quality multimodal cellular data to enable the research community
and pharmaceutical industry to quickly answer complex questions
about disease.
Biological data is complex, fragmented and frequently
inaccessible, with siloed organization and "single use data"
meaning that critical insights may be obscured and groundbreaking
therapeutic discovery hindered.
Enable is building the largest, most comprehensive biological
atlas to index, integrate, and interrogate vast, multimodal
datasets to generate profound, disease-relevant insights and
accelerate discovery. By leveraging the computational power of
generative AI to search these atlases, answers to previously
unanswerable questions can be unlocked.
Proven track record
The two companies first collaborated in 2023, when they
established Ennovate Pharma, which develops precision therapeutics
for autoimmune and inflammatory diseases by leveraging biological
atlases to identify, stratify and understand why certain patients
do not respond to current therapies.
Using Enable's data platform and AI analysis tools, they
revealed vital clinical insights about why some patients with
certain autoimmune diseases fail to respond to standard-of-care
treatments. After 18 months, they are addressing refractory and
non-responder populations in autoimmune disease and have identified
and validated several highly promising targets.
Aaron Mayer, co-founder and
Chief Scientific Officer of Enable Medicine, said:
"Generative biological search of our Atlas of disease is
unlocking the next generation of drug discovery. By working with
General Inception, and its global network of experienced executives
and drug developers, we will be able to jointly accelerate target
discovery, develop optimal patient treatment strategies, and
improve clinical drug positioning."
Venkat Reddy, President of
Enable Medicine and Chief Scientific Officer of General Inception,
added: "After the resounding success of our first
collaboration, we have seen the tremendous power of Enable
Medicine's platform and approach. By investing in Enable Medicine,
and gaining access to their unique data and analytics platform, we
can build a powerful new drug discovery offering."
Professor James Zou, who is an
AI pioneer in life sciences and medicine, and is a member of
Enable's Scientific Advisory Board, said: "Leveraging
AI to help cure seemingly incurable diseases is possible, but only
if we have the right data that can identify the correct biological
targets in the first place. Organizing such data and finding such
targets has historically been a real challenge.
"Enable Medicine has developed a hugely powerful new way of
indexing and interrogating biological data to speed up this vital
process. This partnership with General Inception will ensure its
transformative technology can be put to use by many top
researchers, working in a wide range of areas including cancer,
autoimmune and inflammatory disease."
General Inception and Enable Medicine are now actively seeking
data partnerships with healthcare providers and data repositories
to utilize their joint approach to develop better drugs and patient
treatment strategies.
Notes to Editors
About General Inception
General Inception (GI) is pioneering company creation as an
Igniter company. General Inception partners with extraordinary
scientific founders at the inception of their journey to
efficiently translate their groundbreaking innovations into
transformational companies that address humanity's grand
challenges. As a business co-founder, GI brings together domain and
functional expertise, executive talent, infrastructure and
development resources, and capital to ignite, nurture and scale the
company journey. GI is backed by leading venture capital firms
Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures,
Paladin Capital Group, and Vertical Venture Partners.
For more information, please visit
https://www.generalinception.com/.
About Enable Medicine
At Enable Medicine, our mission is to organize the world's
biological data and make it searchable to generate profound new
insights into health and disease. We are building the largest and
most comprehensive atlas of human biology to index, interconnect
and interrogate diverse data inputs from billions of cells and
across thousands of patient data sets. On the Enable Medicine
platform, scientists use the computational power of AI to search
these atlases and unlock answers to previously unanswerable
questions. Together, we empower those bringing the next generation
of diagnostics and therapeutics forward to deliver better patient
outcomes. To accelerate your discoveries with AI-powered biological
search on the Enable Medicine Platform, visit
https://www.enablemedicine.com.
View original
content:https://www.prnewswire.com/news-releases/general-inception-acquires-enable-medicine-and-announces-strategic-partnership-to-accelerate-drug-discovery-with-ai-led-generative-biological-search-302329523.html
SOURCE General Inception